Key points are not available for this paper at this time.
Evolocumab was well tolerated and effectively reduced plasma LDL-C levels in patients with HoFH and severe HeFH over a median of 4.1 years.
Share your take
Add a clinician perspective alongside expert commentary.
Santos et al. (2020) studied this question.